BiotechTube
Home/PrecisemAb Biotech/Lin Wei‑li
LW

Lin Wei‑li

Operation Consultant

PrecisemAb Biotech

Therapeutic Areas

OncologyImmunology

PrecisemAb Biotech Pipeline

DrugIndicationPhase
PSM101EGFR‑overexpressing solid tumorsPreclinical
PSM915TNF‑α/IL‑1β mediated autoimmune diseasesPreclinical
Bispecific Antibody PlatformImmune checkpoint modulation (PD‑1, CTLA‑4, 4‑1BB, CD28, CD47)Preclinical
ADC PlatformTumor‑selective antibody‑drug conjugatesPreclinical

Leadership Team at PrecisemAb Biotech

LY
Lu Yunqi
Co‑founder & CEO
ZY
Zheng Yi‑an
Co‑founder & CTO
DZ
Deng Zhidun
CMC Consultant
PS
Peter Senter
Chief Scientific Advisor
View full PrecisemAb Biotech profile